Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that was making tender offers for its bonds to the tune of $1 billion, with the aim of reducing its finance costs. The company says that the buyback will be financed “through a future offering of Eurobonds or other senior notes, borrowings under its existing credit facilities and/or other available cash.”
Teva is offering early redemption to holders of four of its bond series: 6.150% Senior Notes due 2036 issued by Teva Pharmaceutical Finance Company, LLC; 3.650% Senior Notes due 2021 issued by Teva Pharmaceutical Finance Company B.V. (“Teva BV”) and 3.650% Senior Notes due 2021 issued by Teva Pharmaceutical Finance IV B.V.; 2.950% Senior Notes due 2022 issued by Teva BV; and 2.400% Senior Notes due 2016.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Published by Globes [online], Israel business news – www.globes-online.com
